Prof Ignasio Wistuba | Professor And Chairman
The University of Texas MD Anderson Cancer Center

Prof Ignasio Wistuba, Professor And Chairman, The University of Texas MD Anderson Cancer Center

Ignacio I. Wistuba, M.D., is Professor and Chair of the Department of Translational Molecular Pathology, with a joint appointment in Thoracic/Head and Neck Medical Oncology, and one of the co-directors of the Khalifa Institute for Personalized Cancer Therapy (IPCT) at M.D.  Anderson Cancer Center in Houston, TX. He is also Director of the Thoracic Molecular Pathology Laboratory, co-leader of the institutional Tissue bank and Pathology Resources, and director of the ECOG-ACRIN Central Biorepository and Pathology Facility. He is a surgical and molecular pathology specialist with a strong record of scientific achievement in lung cancer with over 500 peer-reviewed papers and several book chapters. His research interests include the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer, and the identification of novel molecular targets and validation of biomarkers for targeted- and immune-therapies. At MD Anderson Cancer Center, Dr. Wistuba oversees biomarker studies for lung cancer therapeutic and other solid tumors clinical trials, and he is co-leader of the Moon Shot APOLLO platform. He currently serves as the pathologist of the Lung Cancer Committee for the Southwestern Oncology Group (SWOG), the Lung Cancer Mutation Consortium (LCMC), and chair of the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC).  Dr. Wistuba is the contact PI of three NIH/NCI U24 grants, including the MD Anderson Center for Immune Monitoring and Analysis of Cancer (CIMAC). He serves as senior editor of Cancer Prevention Research (AACR) and Annals of Oncology (ESMO)

Appearances:



December 2 Pre-Congress Workshops @ 13:00

Uses and clinical application of immune profiling assays for cancer:

The use of novel assays and computational methods to analyse the immune system is a very fast-moving field and it is challenging to keep up with the pace of change. Join our Advances in Immune Profiling Assays workshop on 2nd December for an in depth look at the uses and clinical application of new methods to characterise and profile the human immune system for the accelerated development of new therapies.Topics:·Measuring base-line immune function ·Assessing predictive biomarkers for PD1 / PDL1 immunotherapies·How to assess the efficacy and longevity of cellular therapies·Characterising the tumor microenvironment·Discovery of genomic predictors and genomic alterations that promote or suppress immune response·Discovery and development of novel biomarkers

December 3 - Main Congress Day 1 @ 11:40

Development and validation of biomarkers for diagnosis and prediction of response resistance to treatment

last published: 20/Aug/19 15:45 GMT

back to speakers

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com